PeriodontitisPhase 2/3ibuprofenNCT02538237
the Effect of Sub-gingival Irrigation With Ibuprofen 2% Mouthwash in Treatment of Periodontal Diseases.
A Phase 2/3 study testing Ibuprofen 2% mouthwash in people with Periodontitis, run by Islamic Azad University, Sanandaj.
Trial summary
Aim: Use an ibuprofen mouthwash 2% irrigate subgingival in improving the progression of periodontal diseases can be evaluated. Materials and Methods: 22 patients with chronic periodontitis without any systemic disease who have had periodontal disease, and 2 molars that have periodontal pockets deeper than 4 mm on… Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Periodontitis
- What is being tested?
- Ibuprofen 2% mouthwash
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 20 participants
- Where
- No sites listed yet
- Study dates
- Nov 2013to Feb 2015
- Phase
- Phase 2/3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- Healthy volunteers accepted
- Child, Adult, Older adult
Who may be able to join
- The patients systemically healthy were selected for the study.
- The subjects had with periodontal pocket depths of more than 4 mm on at least two teeth in the mandibular molar area that observed on probing.
Who cannot join
- Existing systemic disease;
- Hypersensitive to Ibuprofen;
- The use of any Antibiotic or Anti-inflammatory drugs within the 6 months preceding the beginning of the study;
- Cancer;
- Pregnant or nursing females;
- Smoking; Orthodontic treatments;
Show all 10Show fewer
- Extensive dental restorations;
- Use removal denture;
- Mouth rinses;
- during the entire period of the study.
About this study
Official title: A Randomized, Double-Blind, Split-mouth, Placebo-controlled, Clinical Trial of the Effect of Sub-gingival Irrigation With Ibuprofen Mouthwash in Treatment of Periodontal Diseases
Aim: Use an ibuprofen mouthwash 2% irrigate subgingival in improving the progression of periodontal diseases can be evaluated. Materials and Methods: 22 patients with chronic periodontitis without any systemic disease who have had periodontal disease, and 2 molars that have periodontal pockets deeper than 4 mm on either side of the lower jaw have the clinical examinations. Interventions: For patients who participated in this study, subjects who received oral hygiene instruction and scaling root planing (SRP), After 2 weeks, They were divided into two groups as determined by randomization in this study, Experimental group: ibuprofen 2% mouthwash (made from the Faculty of Pharmaceutical Sciences, Islamic Azad University, Tehran), Control group: placebo, Subgingival Irrigation of ibuprofen 2% mouthwash with an insulin syringe 0.5 ml were rinsed, Clinical measurements including probing depth (PD), clinical attachment levels (CAL), Plaque Index (PI), and Bleeding Index (BI) were recorded and the patients were recalled per once every 2 weeks for 3 months is repetitive, and at the end of 3 months, were evaluated changes in clinical periodontal parameters. ®
Read the detailed description
Patients and methods
Eligible participants were 22 adult patients treated for chronic periodontitis and participating in a supportive periodontal therapy program at the Department of Periodontology of the Dental Clinic of the Islamic Azad University, Dental Branch of Tehran were included in the current study; Recruitment of participants started November 2013 and ended September 2014. The study met the criteria of the Helsinki Declaration of1975, revised in 2008. The survey plan was reviewed and sanctioned, approved by the ethics commission of the Institutional Ethical Committee and Review Board of the Deputy of Research, School of Dentistry. All subjects received the oral and written explanation of the intent of the survey and signed an informed consent after receiving detailed information about the purpose, the benefits, and the possible risks associated with the trial. Individuals satisfying the following entry criteria were recruited:
- Diagnosed suffering from initial (early) to moderate chronic periodontitis;
- Adult patients, more than 28 years old with at least 20 remaining teeth and at least three teeth in each quadrant;
- The presence of at least two residual sites with a probing pocket depth (PPD≥4 mm in two opposite quadrants, which showed bleeding upon probing, radiographically comparable amount of periodontal breakdown and good matching in tooth type, also clinical and minimal radiographic signs of initial (early) to moderate (clinical attachment level of 1 to 3mm.
Exclusion criteria:
Periodontal treatment (non-surgical) the previous six months Systemic diseases; Hypersensitive to Ibuprofen; Systemic antibiotic or anti-inflammatory drugs within the three months preceding the beginning of the study; Pregnant or nursing females; Smoking; No acute periodontal conditions, such as necrotizing periodontal diseases or periodontal abscesses. Mouth rinses during the entire period of the study orthodontic treatments, Use of removable dentures, Extensive dental restorations.
Clinical measurements
The following clinical outcome variables were recorded at baseline, within 7 days to 3 months at the selected teeth, at six sites per tooth, by means of a periodontal probe (William's® probe, Hu-Friedy, USA) by two calibrated blinded examiners:
- Plaque index (PI) using a Silness \& Loe index (18).
- Bleeding on probing (BOP), through the visual inspection 30 s after probing, (Score 0: No bleeding after probing. Score 1: A single discrete bleeding point appears after probing) (19).
- Probing pocket depth (PPD) in millimeters, measured from the gingival margin to the deepest stop of the periodontal pocket at the standardized force.
- Clinical attachment level (CAL), calculated by adding PPD at each site.
Examiner calibration and reproducibility were ensured by duplicating measurements of four periodontitis patients, not included in the study, with a one-day interval, prior to the start of the survey. Repetitive measurements were within a 1mm difference in 91.5 % of the recordings.
Study design and interventions the study was a randomized, placebo-controlled, parallel, split-mouth designed 3-months clinical trial.
Treatment phase I: instruction on oral hygiene procedures after having entered the study, all patients received the following procedures:
- Individualized oral hygiene instructions together with the provision of a new toothbrush, dental floss, and a fluoridated dentifrice.
- Full-mouth periodontal examination ultrasonic instruments and supragingival professional prophylaxis using.
Treatment phase II: After patient selection; using blocked randomization with a block size of 4 and an allocation ratio of 1:1 Block randomization was chosen to prevent too much variability in the number of patients randomized and ensure a reasonably steady flow of patients to each treatment group, Allocation cover was ensured by using container and labeling that did not reveal the content of the trial drug packages who was blind to the therapist and the clinical examiner. Also, the test and placebo mouthwashes had a similar color. Patients were randomly assigned to either the A or B group, while mandibular arches are each divided into two parts (left and right sections);about 60 sites in both groups; individuals received scaling and root planing on the first visit in accordance with the one-stage full-mouth debridement protocol (scaled by means of an ultrasonic device) + professional cleaning; The therapeutic endpoint was defined as a clean root surface without visible or clinically detectable remnants of biofilm or calculus, since two weeks, the mouthwashes were applied into the periodontal pockets with PD ≥4 mm using a syringe with a blunt cannula; and After isolating and drying the selected sites, the assigned ibuprofen mouthwash 2% formulation (made by Islamic Azad university pharmaceutical sciences branch) was subgingivally applied using a needle with a blunt tip and a lateral opening for avoiding any trauma to the tissues. Follow-up visits were scheduled after 0, 7, 14 days, within three months. At these visits, the following clinical outcome variables were recorded at baseline and within seven days to three months at the selected teeth by William's periodontal probe; at six sites per tooth. Oral hygiene was reinforced at each visit, but no further treatment was provided. Within any visit, patients were provided with a full-mouth professional prophylaxis. At every visit, the occurrence of any undesirable side effects or adverse events that could be related to the treatment was recorded, including changing of both teeth and oral mucosa.
Statistical analyses the sample size is calculated using the following formula: α=00.05 and the power (1-β) =80%. For the variability (σ = SD), the value of 0.5 mm was used, considering PPD change from baseline to three months as the main outcome variable, with a desired difference of 1.8 mm. On the basis of these data, the number of enrolled patients to conduct this study was calculated as 12 patients per arm. However, considering the possibility of having a certain amount of drop outpatients (10%), the total number of requests patients was 14 per treatment group. Statistical methods only the data from the selected sites were processed, but the patient was considered the statistical unit. The obtained clinical outcome variables were calculated by the patient, and then by treatment group. For the evaluation of the intragroup changes between baseline and 7, 14, within three months the ANOVA test was used (once the normality of the distribution was proven). Statistical significance was defined as P <0.001. All data were analyzed using a software program (SPSS 19).
- Conditions
- Periodontitis
- Being tested
- placebo, Ibuprofen 2% mouthwash
- Medical subject headings
- Periodontitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
placeboDrug
Also called Ibuprofen 2% mouthwash (made from the Faculty of Pharmaceutical Sciences, Islamic Azad University, Tehran)
the mouthwash(ibuprofen 2% or placebo) Subgingival Irrigation of mouthwash with an insulin syringe 0.5 ml were rinsed.
Ibuprofen 2% mouthwashDrug
| Study group | Role | What they receive |
|---|---|---|
| ibuprofen mouthwash | Experimental | Subgingival Irrigation of ibuprofen 2% mouthwash (made from the Faculty of Pharmaceutical Sciences, Islamic Azad University, Tehran) with an insulin syringe 0.5 ml were rinsed Receives: Drug: Ibuprofen 2% mouthwash |
| placebo mouthwash | Sham comparator | Subgingival Irrigation of placebo 2% mouthwash (made from the Faculty of Pharmaceutical Sciences, Islamic Azad University, Tehran) with an insulin syringe 0.5 ml were rinsed Receives: Drug: placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Reduction of periodontal pocket
periodontal probe
Measured: 15 days
Secondary outcomes (1)
Reduction of bleeding on probing
periodontal probe
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Sep 2015 (estimated)
- Study startNov 2013
- Primary completionAug 2014
- Study completionFeb 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PeriodontitisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2/3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 20 participants (actual)
Sponsor and investigators
- Lead sponsor
- Islamic Azad University, Sanandaj
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Amirhossein Farahmand, Islamic Azad University, Sanandaj
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02538237
- Sponsor's protocol ID
- subgingival irrigation
- Acronym
- ibuprofen
- Status last verified
- Aug 2015
- First submitted
- 29 Aug 2015
- Last updated
- 2 Sep 2015
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 2 Sep 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double-Blind, Split-mouth, Placebo-controlled, Clinical Trial of the Effect of Sub-gingival Irrigation With Ibuprofen Mouthwash in Treatment of Periodontal Diseases
- ClinicalTrials.gov ID
- NCT02538237
- Acronym / sponsor ID
- ibuprofen / subgingival irrigation
- Conditions
- Periodontitis
- Phase
- Phase 2/3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 20 participants (actual)
- Lead sponsor
- Islamic Azad University, SanandajUniversity, hospital or other
- Study start
- Nov 2013
- Primary completion
- Aug 2014 (actual)
- Study completion
- Feb 2015 (actual)
- First posted
- 2 Sep 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Aim: Use an ibuprofen mouthwash 2% irrigate subgingival in improving the progression of periodontal diseases can be evaluated. Materials and Methods: 22 patients with chronic periodontitis without any systemic disease who have had periodontal disease, and 2 molars that have periodontal pockets deeper than 4 mm on either side of the lower jaw have the clinical examinations. Interventions: For patients who participated in this study, subjects who received oral hygiene instruction and scaling root planing (SRP), After 2 weeks, They were divided into two groups as determined by randomization in this study, Experimental group: ibuprofen 2% mouthwash (made from the Faculty of Pharmaceutical Sciences, Islamic Azad University, Tehran), Control group: placebo, Subgingival Irrigation of ibuprofen 2% mouthwash with an insulin syringe 0.5 ml were rinsed, Clinical measurements including probing depth (PD), clinical attachment levels (CAL), Plaque Index (PI), and Bleeding Index (BI) were recorded and the patients were recalled per once every 2 weeks for 3 months is repetitive, and at the end of 3 months, were evaluated changes in clinical periodontal parameters. ®
Detailed description
Patients and methods
Eligible participants were 22 adult patients treated for chronic periodontitis and participating in a supportive periodontal therapy program at the Department of Periodontology of the Dental Clinic of the Islamic Azad University, Dental Branch of Tehran were included in the current study; Recruitment of participants started November 2013 and ended September 2014. The study met the criteria of the Helsinki Declaration of1975, revised in 2008. The survey plan was reviewed and sanctioned, approved by the ethics commission of the Institutional Ethical Committee and Review Board of the Deputy of Research, School of Dentistry. All subjects received the oral and written explanation of the intent of the survey and signed an informed consent after receiving detailed information about the purpose, the benefits, and the possible risks associated with the trial. Individuals satisfying the following entry criteria were recruited:
- Diagnosed suffering from initial (early) to moderate chronic periodontitis;
- Adult patients, more than 28 years old with at least 20 remaining teeth and at least three teeth in each quadrant;
- The presence of at least two residual sites with a probing pocket depth (PPD≥4 mm in two opposite quadrants, which showed bleeding upon probing, radiographically comparable amount of periodontal breakdown and good matching in tooth type, also clinical and minimal radiographic signs of initial (early) to moderate (clinical attachment level of 1 to 3mm.
Exclusion criteria:
Periodontal treatment (non-surgical) the previous six months Systemic diseases; Hypersensitive to Ibuprofen; Systemic antibiotic or anti-inflammatory drugs within the three months preceding the beginning of the study; Pregnant or nursing females; Smoking; No acute periodontal conditions, such as necrotizing periodontal diseases or periodontal abscesses. Mouth rinses during the entire period of the study orthodontic treatments, Use of removable dentures, Extensive dental restorations.
Clinical measurements
The following clinical outcome variables were recorded at baseline, within 7 days to 3 months at the selected teeth, at six sites per tooth, by means of a periodontal probe (William's® probe, Hu-Friedy, USA) by two calibrated blinded examiners:
- Plaque index (PI) using a Silness \& Loe index (18).
- Bleeding on probing (BOP), through the visual inspection 30 s after probing, (Score 0: No bleeding after probing. Score 1: A single discrete bleeding point appears after probing) (19).
- Probing pocket depth (PPD) in millimeters, measured from the gingival margin to the deepest stop of the periodontal pocket at the standardized force.
- Clinical attachment level (CAL), calculated by adding PPD at each site.
Examiner calibration and reproducibility were ensured by duplicating measurements of four periodontitis patients, not included in the study, with a one-day interval, prior to the start of the survey. Repetitive measurements were within a 1mm difference in 91.5 % of the recordings.
Study design and interventions the study was a randomized, placebo-controlled, parallel, split-mouth designed 3-months clinical trial.
Treatment phase I: instruction on oral hygiene procedures after having entered the study, all patients received the following procedures:
- Individualized oral hygiene instructions together with the provision of a new toothbrush, dental floss, and a fluoridated dentifrice.
- Full-mouth periodontal examination ultrasonic instruments and supragingival professional prophylaxis using.
Treatment phase II: After patient selection; using blocked randomization with a block size of 4 and an allocation ratio of 1:1 Block randomization was chosen to prevent too much variability in the number of patients randomized and ensure a reasonably steady flow of patients to each treatment group, Allocation cover was ensured by using container and labeling that did not reveal the content of the trial drug packages who was blind to the therapist and the clinical examiner. Also, the test and placebo mouthwashes had a similar color. Patients were randomly assigned to either the A or B group, while mandibular arches are each divided into two parts (left and right sections);about 60 sites in both groups; individuals received scaling and root planing on the first visit in accordance with the one-stage full-mouth debridement protocol (scaled by means of an ultrasonic device) + professional cleaning; The therapeutic endpoint was defined as a clean root surface without visible or clinically detectable remnants of biofilm or calculus, since two weeks, the mouthwashes were applied into the periodontal pockets with PD ≥4 mm using a syringe with a blunt cannula; and After isolating and drying the selected sites, the assigned ibuprofen mouthwash 2% formulation (made by Islamic Azad university pharmaceutical sciences branch) was subgingivally applied using a needle with a blunt tip and a lateral opening for avoiding any trauma to the tissues. Follow-up visits were scheduled after 0, 7, 14 days, within three months. At these visits, the following clinical outcome variables were recorded at baseline and within seven days to three months at the selected teeth by William's periodontal probe; at six sites per tooth. Oral hygiene was reinforced at each visit, but no further treatment was provided. Within any visit, patients were provided with a full-mouth professional prophylaxis. At every visit, the occurrence of any undesirable side effects or adverse events that could be related to the treatment was recorded, including changing of both teeth and oral mucosa.
Statistical analyses the sample size is calculated using the following formula: α=00.05 and the power (1-β) =80%. For the variability (σ = SD), the value of 0.5 mm was used, considering PPD change from baseline to three months as the main outcome variable, with a desired difference of 1.8 mm. On the basis of these data, the number of enrolled patients to conduct this study was calculated as 12 patients per arm. However, considering the possibility of having a certain amount of drop outpatients (10%), the total number of requests patients was 14 per treatment group. Statistical methods only the data from the selected sites were processed, but the patient was considered the statistical unit. The obtained clinical outcome variables were calculated by the patient, and then by treatment group. For the evaluation of the intragroup changes between baseline and 7, 14, within three months the ANOVA test was used (once the normality of the distribution was proven). Statistical significance was defined as P <0.001. All data were analyzed using a software program (SPSS 19).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| ibuprofen mouthwash | Experimental | Drug: Ibuprofen 2% mouthwashSubgingival Irrigation of ibuprofen 2% mouthwash (made from the Faculty of Pharmaceutical Sciences, Islamic Azad University, Tehran) with an insulin syringe 0.5 ml were rinsed |
| placebo mouthwash | Sham comparator | Drug: placeboSubgingival Irrigation of placebo 2% mouthwash (made from the Faculty of Pharmaceutical Sciences, Islamic Azad University, Tehran) with an insulin syringe 0.5 ml were rinsed |
Who may qualify
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (2 listed)
- The patients systemically healthy were selected for the study.
- The subjects had with periodontal pocket depths of more than 4 mm on at least two teeth in the mandibular molar area that observed on probing.
Key exclusion criteria (10 listed)
- Existing systemic disease;
- Hypersensitive to Ibuprofen;
- The use of any Antibiotic or Anti-inflammatory drugs within the 6 months preceding the beginning of the study;
- Cancer;
- Pregnant or nursing females;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| placeboAlso: Ibuprofen 2% mouthwash (made from the Faculty of Pharmaceutical Sciences, Islamic Azad University, Tehran)the mouthwash(ibuprofen 2% or placebo) Subgingival Irrigation of mouthwash with an insulin syringe 0.5 ml were rinsed. | Drug | placebo mouthwash |
| Ibuprofen 2% mouthwash | Drug | ibuprofen mouthwash |
Primary outcome
Reduction of periodontal pocket
Time frame: 15 days
periodontal probe
1 secondary outcome
Reduction of bleeding on probing
Time frame: 3 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Sep 2015.
Related trials for Periodontitis
Recruiting
Effect of Cryotherapeutic and Nanotherapeutic Sodium Hypochlorite on Post-Operative Endodontic Pain.
Symptomatic Irreversible Pulpitis, Symptomatic Apical Periodontitis
Active, not recruitingObservational study
A Retrospective Comparative Evaluation of Omega-3 and Resveratrol Supplementation in Patients With Periodontitis
Periodontitis
Recruiting
Probiotics Versus Antibiotics as an Adjuvant to Non-surgical Periodontal Treatment Among Smokers With Stage II, Grade B Periodontitis
Probiotics, Antibiotics
Recruiting
Effects of Different Activation Techniques on Antimicrobial Photodynamic Therapy in Apical Periodontitis
Apical Periodontitis, Endodontic Retreatment
Recruiting
Ozone Gel Versus Chlorohexidine Gel as an Adjunct to Non-Surgical Treatment of Stage II Periodontitis Grade B Among Smokers Patients
Ozone Gel, Chlorohexidine Gel
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A Phase 2/3 study testing Ibuprofen 2% mouthwash in people with Periodontitis, run by Islamic Azad University, Sanandaj.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Sep 2015. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Reduction of periodontal pocket (time frame: 15 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Sep 2015.